Urine Drug Testing Patents: Leaders, Trends & White Space 2026
- 34 families at the top. one assignee holds 34 of the tracked families, against a single filing each at fifth and tenth place — a steep drop rather than a gradual taper.
- Filings peaked in 2019 at 24. activity has not returned to that level since, though 2025–2026 counts are still incomplete due to publication lag.
- Chemistry classes dominate the filing mix. A61P and C07K cover 69.6% and 54.3% of the 46 records respectively, while G01N — the class that actually reads on assay and testing apparatus — sits at just 17.4%.
Filing growth compares 2021 (2 records) with 2024 (0) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field.
What this landscape covers
This landscape tracks 46 published records at the intersection of urine drug screening, toxicology immunoassay and the legal-defensibility mechanics that separate a screening result from a confirmatory one: cutoff concentration, cross-reactivity, adulteration detection, confirmatory mass spectrometry and chain of custody. The scope spans 2015 through the 2026-07-31 data cut-off, with the most recent one to two years understated because publication trails filing by roughly 18 months.
The record set is small enough that a single assignee's filing decisions move the whole picture, and the technology composition leans further toward therapeutic and biologic claim language than toward instrumentation — a detail worth checking before assuming this is primarily an assay-hardware field.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 46-record set: filings by year, and the IPC subclasses those records carry. Because a record can sit in more than one class, the class shares add up to well over 100% of the record total.
Filing trend, 2017-2026
Filings rose to a peak of 24 in 2019, then fell away; the tracked growth figure for 2021 to 2024 is -100%, and 2025-2026 remain partial due to publication lag rather than a confirmed continued decline.
Technology composition by IPC subclass
A61P (therapeutic activity) and C07K (peptides and proteins) together dominate the mix, ahead of A61K (medicinal preparations). G01N, the class most associated with material analysis and testing apparatus, covers 17.4% of the 46 records, with A61B, B01L, C12N and G06F each in single digits.
Shares are the percentage of the 46 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Urine Drug and Toxicology Screening with Eureka
This page is one run against one query. Ask Eureka your own question about urine drug and toxicology screening and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative and most-cited filings
US20060057728A1 — Method to prevent urine specimen and other specimen substitution in substance use screening
Substitution of specimens may be detected and even prevented by adding randomization to the collection and routing of specimens. A test taker ingests an entity whose nature is concealed from the test taker and from personnel involved in collection, so neither party knows the fluorescence behaviour expected of an unsubstituted sample. The identity of the ingestible entity is randomized and closely held, for example through bar coding or an undetectable marker scheme.Filed by Katz, Michael; published 2006-03-16.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20040184954A1 | Lateral flow immunoassay devices for testing saliva and other liquid samples and methods of use of same | 227 |
| 2 | US20040184965A1 | Testing cup | 20 |
| 3 | US20030007892A1 | UA cup | 20 |
| 4 | US20050053519A1 | Delta cup | 12 |
| 5 | US20190309079A1 | Methods of treatment using a leptin receptor agonist antibody | 10 |
| 6 | US20180231517A1 | PAH antibodies and uses thereof | 6 |
| 7 | WO2016196638A2 | PAH antibodies and uses thereof | 6 |
| 8 | US11608381B2 | Methods of treatment using a leptin receptor agonist antibody | 4 |
| 9 | US20060057728A1 | Method to prevent urine specimen and other specimen substitution in substance use screening | 3 |
| 10 | US20220280641A1 | Methods of treatment using a leptin receptor agonist antibody | 2 |
Citation counts favour older filings in any searched corpus; treat them as a signal of influence, not of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for filing strategy
Three patterns stand out once the record count, the assignee ranking and the class shares are read together.
One assignee dominates a small field
The leading assignee holds 34 of the ranked families, while the fifth- and tenth-ranked assignees each hold a single family. That is a cliff, not a gradual taper, and it means most of the competitive intelligence value in this dataset sits with one filer's portfolio rather than a spread of comparable players.
Activity peaked in 2019 and has not returned
Filings reached 24 in the peak year of 2019 and the tracked 2021-to-2024 growth figure is -100%. Because publication lags filing by around 18 months, the 2025-2026 counts are still filling in and should not be read as a confirmed further decline.
Chemistry claims outweigh assay-hardware claims
A61P and C07K, covering therapeutic activity and peptide chemistry, appear in 69.6% and 54.3% of the 46 records respectively. G01N, the class that covers material analysis and testing methods, appears in only 17.4% — suggesting the tracked filings skew toward the substances being screened for or treated, not the testing apparatus itself.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to urine drug and toxicology screening, with the prior art for and against each one.
Who is filing, and where the field is open
The assignee ranking returned by this dataset covers 10 companies and individual filers; it is the complete ranking for this search, not a top-50 or top-100 cut.
A single dominant filer
One assignee accounts for 34 of the tracked families. Recent-year momentum for this assignee is recorded at 0% year-on-year in the latest year, so the size of the lead reflects historical filing rather than fresh activity.
Everyone else files once or twice
Below the leader, the ranked assignees drop to a single family each by fifth place, continuing through tenth. Several of the named co-assignee pairs — for instance Yang Ying with Wu Yuchang, and separately with Tung Hsaioho Edward — appear only once, consistent with individual inventors or small teams rather than sustained corporate programmes.
US-centred filing with a thin international spread
The United States accounts for 13 of the tracked receiving-office filings, ahead of Europe (EPO) at 4, Australia and WIPO (PCT) at 3 each, and Hong Kong and Israel at 2 each. That pattern points to a domestically-focused field rather than one built around broad multi-jurisdiction families.
| Assignee | Recent year | YoY |
|---|---|---|
| Regeneron Pharmaceuticals | 1 | 0% |
| Xiulan Education Fund Management Company | 0 | — |
| SMITH JACK V | 0 | — |
| FIT 4 DUTY | 0 | — |
| YANG YING | 0 | — |
| WU YUCHANG | 0 | — |
| TUNG HSAIOHO EDWARD | 0 | — |
| MCCARTHY ELEANOR M S | 0 | — |
Where to take this
The dataset points to a concentrated field with an ageing peak and a thin instrumentation layer. Two directions follow from that.
Check the leader's claim boundaries before filing near G01N
With one assignee holding 34 of the ranked families, any new filing in adulteration detection or cross-reactivity should first map that portfolio's independent claims rather than assume the class is open because filing counts are low.
Explore the leader's portfolio in EurekaRevisit assay-hardware and digital chain-of-custody claims
G01N, B01L and G06F together cover a small share of the 46 records despite being central to defensible testing workflows. That gap is worth validating against the full claim text before assuming freedom to operate.
Run a white-space search in EurekaCommon questions about this landscape
It is concentrated at the top but the concentration cannot be expressed as a clean percentage from this dataset, because the assignee ranking and the record total are counted in different units. What can be said is that the leading assignee holds 34 of the ranked families while the fifth- and tenth-ranked assignees each hold just one. That is a steep drop, meaning most competitive intelligence value sits with a single filer rather than being spread across several comparable players.
Filing activity peaked in 2019 at 24 records within this dataset. The tracked growth figure from 2021 to 2024 shows a -100% change, but 2025 and 2026 counts are still incomplete because publication typically lags actual filing by around 18 months. Readers should not treat the most recent one or two years as evidence of a continued decline until later data fills in.
Based on IPC composition, the substances and therapeutic activity dominate: A61P (therapeutic activity of compounds) appears in 69.6% of the 46 records and C07K (peptides and proteins) in 54.3%. G01N, the class most associated with material analysis and testing methods, covers only 17.4% of records. That suggests filings in this set lean toward the chemistry and biology of what is being screened for, rather than the assay hardware itself.
US20060057728A1, filed by Katz, Michael and published in 2006, covers a method for preventing specimen substitution in substance-use screening by randomizing an ingestible entity given to the test taker and keeping its detection characteristics — such as fluorescence behaviour — concealed from both the test taker and the personnel handling the sample. It is a specimen-integrity and chain-of-custody method rather than an assay-chemistry patent. Anyone building a substitution-prevention protocol involving concealed markers or randomized ingestible tracers should review its claim scope directly.
The class shares point to comparatively thin coverage in G01N (material analysis and testing, 17.4% of 46 records), B01L (lab apparatus, 4.3%) and G06F (digital data processing, 4.3%), against a field dominated by A61P and C07K chemistry classes. That pattern suggests point-of-care apparatus design, digital chain-of-custody tracking and confirmatory mass-spectrometry workflow claims are less crowded than the therapeutic and peptide-chemistry space, though this should be confirmed against full claim text before filing.
Research Urine Drug and Toxicology Screening in depth with Eureka
Go past this page: query the whole urine drug and toxicology screening corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.